Question 1

What is TB-500?

Accepted Answer

TB-500 is a synthetic peptide analog of the naturally occurring protein thymosin-beta-4. It is studied in preclinical research for its role in actin cytoskeletal regulation through G-actin sequestration and for its documented effects on cellular migration, tissue remodeling, and angiogenesis in animal and cell culture models. TB-500 is for in vitro research use only and is not approved for human therapeutic application.

Question 2

How does TB-500 work in research models?

Accepted Answer

In preclinical research models, TB-500 acts primarily by binding G-actin monomers, preventing their polymerization into filamentous F-actin. This actin sequestration reduces cytoskeletal tension and facilitates cellular migration. Published research also documents TB-500 interacting with integrin-linked kinase signaling through the PINCH-ILK-parvin complex, supporting cell survival and matrix adhesion. See the full mechanism overview at /how-tb-500-works/.

Question 3

What has TB-500 been studied for in published preclinical research?

Accepted Answer

Published preclinical research has examined TB-500 in dermal wound healing models (accelerated closure and collagen organization), cardiac injury models (reduced infarct area and cardiomyocyte protection), skeletal muscle and tendon repair paradigms, CNS and peripheral nerve injury models, and angiogenesis research through angiopoietin receptor pathway activation.

Question 4

What is the half-life of TB-500 in research models?

Accepted Answer

Published pharmacokinetic studies have documented TB-500 with relatively extended plasma stability compared to smaller peptides, attributed to actin binding which may extend circulating half-life. Published preclinical data suggests several hours of circulating half-life in rodent models, though specific values vary across published measurement methodologies. Researchers should reference published pharmacokinetic literature for model-specific half-life data.

Question 5

How is TB-500 stored for research use?

Accepted Answer

Research-grade TB-500 should be stored as lyophilized powder at -20 degrees Celsius for long-term stability. Short-term storage at 2 to 8 degrees Celsius is acceptable under dry conditions. Reconstituted solutions should be prepared under sterile conditions appropriate for the intended research application and used according to established peptide handling protocols for research use.

Question 6

What purity standard should research-grade TB-500 meet?

Accepted Answer

Research-grade TB-500 is characterized by HPLC purity analysis with a standard specification of at least 98% purity. Certificate of Analysis documentation should confirm purity result, mass spectrometry molecular weight verification, and batch identification. Researchers should request COA documentation when sourcing TB-500 for in vitro research applications.

Question 7

Is TB-500 water soluble?

Accepted Answer

TB-500 is generally water soluble and is typically reconstituted in sterile saline or bacteriostatic water for research use. Published preclinical methodology sections describe aqueous vehicle preparations for rodent model administration. For cell culture research, TB-500 is reconstituted in sterile water or PBS and diluted to working concentration in cell culture media without the need for organic solvent co-solvents.

Question 8

What key research studies have been published on TB-500 and thymosin-beta-4?

Accepted Answer

The TB-500 research literature builds on the broader thymosin-beta-4 body of work including foundational publications by Goldstein and colleagues on thymosin-beta-4 biology, cardiac repair research documenting reduced infarct area in rodent models, and wound healing studies characterizing accelerated closure through cellular migration mechanisms. Researchers can search PubMed for "thymosin beta 4" and "TB-500" to access indexed publications.

Question 9

How does TB-500 compare to BPC-157 in research?

Accepted Answer

TB-500 and BPC-157 represent complementary tissue repair mechanisms in the published preclinical literature. TB-500 acts systemically through actin sequestration and ILK pathway modulation. BPC-157 acts locally through nitric oxide pathway and VEGF signaling at injury sites. Published combination research documents additive effects in rodent injury models. See the BPC-157 vs TB-500 comparison in the Research Library for detailed mechanism comparison.

Question 10

What research has examined TB-500 in cardiac models?

Accepted Answer

Published cardiac injury research has documented TB-500 reducing myocardial infarct area and supporting cardiomyocyte survival in rodent myocardial injury paradigms. These effects have been attributed to the actin modulation and anti-apoptotic signaling properties documented in the thymosin-beta-4 and TB-500 literature. Cardiac model research has used left anterior descending artery ligation and ischemia-reperfusion paradigms as published model platforms.

Question 11

Where can researchers source TB-500 for in vitro research?

Accepted Answer

Research-grade TB-500 for in vitro use is available from Spartan Peptides with at least 98% HPLC-verified purity and Certificate of Analysis documentation. All TB-500 is for in vitro research use only and is not intended for human consumption. Researchers should source TB-500 from suppliers providing independent batch testing and sequence verification documentation.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research

TB-500 Frequently Asked Questions

Explore Full Research Index